

## **CEFALEXIN**

Read in conjunction with **Disclaimer** 

Formulary: Unrestricted						
Presentation	Powder for oral suspension: 250 mg/5 mL = 50 mg/mL					
Classification	First generation cephalosporin antibiotic.					
Indication	<ul> <li>Treatment of mild infections due to susceptible organisms.</li> <li>Prophylaxis of urinary tract infection in at risk patients.</li> </ul>					
<ul> <li>Use with caution in patients with hypersensitivity or mild adverse reactions to penicillins or carbapenems as cross-reactivity can occur (e.g. rash).</li> <li>Cefalexin may cause a false positive Coombs test.</li> </ul>						
Monitoring	Monitor renal, hepatic and full blood count with prolonged use.					
	Common or infrequent: Diarrhoea, vomiting, rash, abdominal pain.					
Adverse Effects	Rare: Immunologic or anaphylactic reactions, neurotoxicity, blood dyscrasias, cholestatic hepatitis, antibiotic associated colitis, renal impairment.					
Storage & Stability	<b>Powder for reconstitution:</b> Store at room temperature, below 25°C. Protect from light and moisture.					
	<ul> <li>Reconstituted suspension: Refrigerate at 2 to 8°C, do not freeze</li> <li>Discard 14 days after reconstitution.</li> </ul>					

	Presentation	mg/mL				
		Treatment of mild infections due to susceptible organisms:				7
		Postnatal Age	Dose	Frequency		
AL	Dosage	Less than 7 days	25 mg/kg/dose	Every 12 hours		
		7 to 21 days	25 mg/kg/dose	Every 8 hours		
ORAL		Greater than 21 days	25 mg/kg/dose	Every 6 hours		
		Do not exceed 125 mg per dose.				
		Prophylaxis of urinary tract infections: 12.5 mg/kg once daily at night.				
	Dose	No dosing guidelines are published for preterm neonates.				
	Adjustment	<ul> <li>Renal impairment: Consider increasing dosing interval in significant renal impairment.</li> </ul>				

	Reconstitution steps differ between brands, refer to product packaging for reconstitution instructions.  For Cefalexin Sandoz® 250 mg/5 mL suspension:	
Preparation	<ol> <li>Invert bottle and tap to loosen granules.</li> <li>Add 63mL of sterile water to the bottle.</li> <li>Close and shake well.</li> </ol>	
Administration	<ul> <li>Shake well before each use.</li> <li>Draw prescribed dose into oral/enteral syringe.</li> <li>Can be given Oral/OGT/NGT.</li> <li>May be given anytime in relation to feeds.</li> </ul>	

## Related Policies, Procedures, and Guidelines

**Pharmaceutical and Medicines Management Guidelines:** 

<u>CAHS Neonatology – Medication Administration Guideline</u>

WNHS Cold Chain Management for Medications and Vaccines

**CAHS Medication Refrigerators and Freezers** 

## References

AusDI. Cefalexin Sandoz. In: AusDI By Medical Director [Internet]. Australia: AusDI by Medical Director; 2024 [cited 2025 Sep 02]. Available from: <a href="https://www.ausdi.com/">https://www.ausdi.com/</a>

Australasian Neonatal Medicines Formulary (ANMF). Cefalexin. In: Australasian Neonatal Medicines Formulary [Internet]. [Sydney, New South Wales; 2020 [cited 2025 Sep 01]. Available from: www.anmfonline.org

Australian Medicines Handbook. Cefalexin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2025 [cited 2025 Sep 02]. Available from: <a href="https://amhonline.amh.net.au/">https://amhonline.amh.net.au/</a>

British National Formulary. BNF for Children. 2023-24 ed. London, UK: BMJ Group and Pharmaceutical Press; 2023. p. 366-367.

Ainsworth SB. Neonatal formulary 7: drug use in pregnancy and the first year of life. Seventh ed. Chichester (West Sussex): John Wiley & Sons Inc.; 2015. 631 p. 134.

## **Document history**

Keywords	Cefalexin, cephalexin, cephalosporin, Cephalex, Keflex, Ibilex, antibiotic, UTI, urinary tract infection							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate							
Version Info:	V4.0 - New template, full review, minor changes.							
Date First Issued:	08/2013	Last Reviewed:	02/09/2025		Review Date:	02/09/2030		
Endorsed by:	Neonatal Directorate Management Group				Date:	23/09/2025		
NSQHS Standards Applicable:	Std 1: Clini	ical Governance	Std 4: Medication Safety					
Printed or personally saved electronic copies of this document are considered uncontrolled.  Access the current version from WNHS HealthPoint.								

This document can be made available in alternative formats on request for a person with a disability.

© North Metropolitan Health Service 2025